April 30, 2012 / 7:03 AM / 6 years ago

Warner Chilcott weighs sale, other options: report

(Reuters) - Warner Chilcott is evaluating options, including a possible sale of the company, after receiving interest from strategic and private-equity buyers, Bloomberg News reported on Monday.

Goldman Sachs is helping the Nasdaq-listed drugmaker assess interest, said the news service, citing people with knowledge of the matter. Warner Chilcott is also considering paying a dividend as an alternative to a sale, one person said.

Warner Chilcott’s stock rose 8 percent to $18.79 on Friday on takeover speculation, giving it a market capitalization of $4.7 billion, after the Times of London said in a market report there was talk Bayer might bid $32 a share.

Reuters reported on April 25 that Bayer was nearing a multibillion-dollar acquisition to bolster its healthcare division, citing three people close to the planned transaction.

Warner Chilcott focuses on women’s health care, dermatology, urology and gastroenterology.

Reporting by Ben Hirschler

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below